The SBIR/STTR Oversight Act tightens and broadens reporting for the SBIR and STTR programs. It requires annual, congressionally targeted reporting and online publication by agencies; mandates a Comptroller General review of diversification and commercialization; extends the deadline for award-timeliness reporting; and creates a NIH pilot program to accelerate SBIR/STTR awards with standardized procedures and a near-90-day funding timeline.
The bill also adds definitions of new entrants and underrepresented groups to sharpen how participation is measured. This package signals a stronger emphasis on transparency, inclusion, and speed, with a formal evaluation framework to track outcomes.
At a Glance
What It Does
The act expands reporting requirements for SBIR and STTR programs to include specific congressional committees and public online publication, and it creates new evaluative and timing-related obligations across agencies, including NIH.
Who It Affects
Federal agencies running SBIR/STTR programs, small businesses participating in those programs (including new entrants and underrepresented groups), and the Congressional Small Business committees. NIH offices administering SBIR/STTR are directly affected by the pilot program and timing rules.
Why It Matters
By expanding oversight, the bill aims to improve diversification, commercialization outcomes, and information availability for policymakers, program managers, and prospective applicants.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The bill strengthens oversight of the SBIR and STTR programs by forcing more regular scrutiny and public transparency. Section 2 expands who must report to Congress on SBIR/STTR activities and requires that these reports be published on agency websites as soon as practicable.
It adds the House and Senate Small Business Committee chairs to the reporting chain and updates the language to ensure timely online publication. Section 3 requires the Comptroller General to deliver within three years a detailed evaluation of how SBIR/STTR awards are reaching new entrants and broad underrepresented groups, including demographics, agency outreach, and alignment with agency priorities for research and commercialization.
Section 4 lengthens the prescribed window for reporting on award timeliness from 3 years to 11 years and requires agencies to disclose the average and median times to review and finalize SBIR/STTR proposals. Section 5 creates a National Institutes of Health pilot program aimed at speeding SBIR/STTR awards, with a goal of reducing time from notice to funding to about 90 days, standardized procedures across NIH awarding offices, and a peer-review approach to assess scientific merit and potential for commercialization.
The NIH pilot ends in 2030, and an independent evaluation of the pilot is due within three years. The overall thrust is to improve transparency, diversify participation, and speed promising projects toward funding, while giving policymakers better data to assess program impact.
The Five Things You Need to Know
The bill expands reporting recipients to include House and Senate Small Business committees and requires online publication by agencies.
The GAO must deliver a diversification and commercialization assessment within three years, covering demographics, outreach, and topic development.
The requirement to report on award timeliness extends from 3 years to 11 years, and must include average and median review times.
A NIH-led pilot program will speed SBIR/STTR awards, aiming for near-90-day funding after notice with standardized procedures and peer review.
The NIH pilot has a sunset date of September 30, 2030 and requires an evaluation within three years on its procedures and impact on timing.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Expanded annual reporting to Congress and online publication
Section 2 amends the Small Business Act to broaden who must be informed about SBIR and STTR activities and to require timely online publication of those reports. Specifically, it adds the House Committee on Small Business and the Senate Committee on Small Business and Entrepreneurship to the reporting list, inserts a clarifying comma after the Administration reference, and requires publication of the report on the relevant agency’s website as soon as practicable. These changes increase visibility into program operations and outcomes across the entire SBIR/STTR ecosystem.
Comptroller General report on diversification and commercialization
Section 3 directs the Comptroller General to produce a report within three years evaluating the effectiveness of SBIR and STTR in diversifying participation and advancing commercialization. The content includes demographics of award recipients (including new entrants and underrepresented groups), agencies’ outreach efforts, topic solicitation and applicant attraction, commercialization support, and alignment of awards with each agency’s priorities. The aim is to identify gaps and guide improvements in representation and impact.
Extend the report on award timeliness
Section 4 amends the award-timeliness reporting requirement by extending the lookback window from 3 years to 11 years and adding a new element: the average and median time agencies take to review and decide on SBIR/STTR proposals. This broadens the historical perspective and provides a more stable measurement of program efficiency over time.
Pilot program to accelerate NIH SBIR/STTR awards
Section 5 adds a new NIH pilot to shorten award timelines. Within one year of enactment, NIH must establish a pilot to reduce the time from notice to final funding by as close to 90 days as possible, using standardized procedures across NIH awarding offices. The pilot allows merit review to leverage existing peer-review processes and deemed compliance with SBIR/STTR requirements. The pilot terminates on September 30, 2030, with an evaluation due within three years evaluating the procedures and their effect on award timing.
This bill is one of many.
Codify tracks hundreds of bills on Government across all five countries.
Explore Government in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- New entrant small businesses seeking SBIR/STTR funding, particularly those from underrepresented groups, benefiting from improved outreach and topic development.
- Women-owned small businesses and those owned and controlled by socially and economically disadvantaged individuals, due to expanded opportunities and data-driven targeting of funding opportunities.
- Federal agencies administering SBIR/STTR programs gain clearer oversight and data to guide policy decisions and program design.
- National Institutes of Health awarding offices and other agencies implementing the NIH pilot benefit from clearer timelines and streamlined processes that can accelerate commercialization.
- Congressional small business committees gain more timely, public-facing information to inform oversight and policy adjustments.
Who Bears the Cost
- Federal agencies with SBIR/STTR programs will incur additional reporting and publication burdens.
- NIH and other awarding offices participating in the 90-day funding pilot must rework processes and allocate resources for standardized procedures and reviews.
- The GAO and related support offices will shoulder additional workload to prepare and analyze diversification and timing reports.
- Smaller or resource-constrained businesses may experience more stringent data collection requirements and reporting expectations from applicants and awardees.
Key Issues
The Core Tension
Balancing the desire for accountability and faster funding with the need to maintain rigorous merit review and equitable access across diverse participants.
The bill’s push for transparency and speed creates legitimate policy gains but also practical tensions. Requiring rapid publication and detailed demographic data increases the administrative load on agencies, which may strain existing staff and systems.
The NIH pilot’s accelerated timelines rely on streamlined processes and possibly adjusted merit-review standards; while this can speed funding, it may also compress review cycles and shift attention from thorough evaluation to speed. The expansion of the GAO’s evaluation scope improves accountability, but it raises questions about data consistency across agencies with different SBIR/STTR implementations.
Lastly, extending the timeliness reporting window to 11 years provides a longer historical lens, but could obscure short-term fluctuations or recent improvements in program performance.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.